| Literature DB >> 35741271 |
Ying Zhao1,2, Ze-Yu Wang3, Xue-Dong Zhang4, Yao Wang1,2, Wen-Hang Yang1,2, Ying-Chun Xu1,2.
Abstract
This study aimed to assess the diagnostic values of peptidoglycan (PGN), lipopolysaccharide (LPS) and (1,3)-Beta-D-Glucan (BDG) in patients with suspected bloodstream infection. We collected 493 heparin anticoagulant samples from patients undergoing blood culture in Peking Union Medical College Hospital from November 2020 to March 2021. The PGN, LPS, and BDG in the plasma were detected using an automatic enzyme labeling analyzer, GLP-F300. The diagnostic efficacy for PGN, LPS, and BDG were assessed by calculating the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). This study validated that not only common bacteria and fungi, but also some rare bacteria and fungi, could be detected by testing the PGN, LPS, and BDG, in the plasma. The sensitivity, specificity, and total coincidence rate were 83.3%, 95.6%, and 94.5% for PGN; 77.9%, 95.1%, and 92.1% for LPS; and 83.8%, 96.9%, and 95.9% for BDG, respectively, which were consistent with the clinical diagnosis. The positive rates for PGN, LPS, and BDG and the multi-marker detection approach for PGN, LPS, and BDG individually were 11.16%, 17.65%, and 9.13%, and 32.86% significantly higher than that of the blood culture (p < 0.05). The AUC values for PGN, LPS, and BDG were 0.881 (0.814-0.948), 0.871 (0.816-0.925), and 0.897 (0.825-0.969), separately, which were higher than that of C-reactive protein (0.594 [0.530-0.659]) and procalcitonin (0.648 [0.587-0.708]). Plasma PGN, LPS, and BDG performs well in the early diagnosis of bloodstream infections caused by Gram-positive and Gram-negative bacterial and fungal pathogens.Entities:
Keywords: (1,3)-Beta-D-Glucan; bloodstream infection; diagnostic efficacy; lipopolysaccharide; peptidoglycan
Year: 2022 PMID: 35741271 PMCID: PMC9221811 DOI: 10.3390/diagnostics12061461
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
The age and sex of the patients.
| Factors | Patients with Definite BSI by Blood Culture Combined with Clinical Diagnosis | BSI Negative Patients | Multi-Marker Positive Patients (PGN/LPS/BDG) | Multi-Marker Negative Patients (PGN/LPS/BDG) | |
|---|---|---|---|---|---|
| Age (±SD), years | 58.76 ± 16.77 | 51.97 ± 19.73 | <0.001 | ||
| Sex (male/female) | 86/60 | 186/161 | 0.321 | ||
| Age (±SD), years | 58.76 ± 16.77 | 52.08 ± 19.62 | 0.014 | ||
| Sex (male/female) | 92/69 | 180/152 | 0.563 |
Results of the blood culture combined with the clinical diagnosis and the efficacy of PGN, LPS, and BDG in the diagnosis of BSIs.
| Blood Culture Combined with Clinical Diagnosis | PGN | LPS | BDG | ||||||
|---|---|---|---|---|---|---|---|---|---|
| + | − | Total | + | − | Total | + | − | Total | |
| + | 35 | 7 | 42 | 67 | 19 | 86 | 31 | 6 | 37 |
| − | 20 | 431 | 451 | 20 | 387 | 407 | 14 | 442 | 456 |
| Total | 55 | 438 | 493 | 87 | 406 | 493 | 45 | 448 | 493 |
Results of the related indexes in PGN, LPS, and BDG and the multi-marker detection approach.
| PGN | LPS | BDG | Multi-Marker Detection Approach | |
|---|---|---|---|---|
| Sensitivity | 83.3% | 77.9% | 83.8% | 81.1% |
| Specificity | 95.6% | 95.1% | 96.9% | 88.7% |
| PPV | 63.6% | 77.0% | 68.9% | 75.5% |
| NPV | 98.4% | 95.3% | 98.7% | 91.6% |
| Total Coincidence Rate | 94.5% | 92.1% | 95.9% | 86.4% |
| Kappa Index | 0.692 | 0.727 | 0.734 | 0.683 |
a. Cut off value. b. 95% CI. The reason the coincidence rate of multi-marker detection approach was lower than that of single test. In the case of the multi-marker detection approach, it was judged as qualified only if all the single test results were correct, and it was judged as unqualified if any item was unqualified. Sensitivity = number of true positive cases/(number of true positive cases + number of false negative cases) × 100%; specificity = number of true negative cases/(number of true negative cases + number of false positive cases) × 100%; Positive predictive value (PPV) = number of true positive cases/(number of true positive cases + number of false positive cases) × 100%; Negative predictive value (NPV) = number of true negative cases/(number of true negative cases + number of false negative cases) × 100%; Total coincidence rate = (number of true positive cases + number of true negative cases)/total number of cases × 100%.
Positive rates of the blood culture and the multi-marker approach detection.
| Method | Gram-Positive Bacteria | Gram-Negative Bacteria | Fungi | Bacteria and Fungi |
|---|---|---|---|---|
| Blood culture | 6.49% (32/493) | 12.17% (60/493) | 1.62% (8/493) | 19.88% (98/493) |
| PGN/LPS/BDG detection | 11.16% (55/493) | 17.65% (87/493) | 9.13% (45/493) | 32.86% (162/493) |
Results of the positive rate in PCT judged according to different cut off values.
| Judgment Criteria of Cut Off Values | Positive Rate in Total Samples (376 Cases) | The Positive Rate in Samples (116 Cases) with Bacteria and Fungi Positive by Blood Culture Combined with Clinical Diagnosis |
|---|---|---|
| >0.25 ng/mL | 62.0% | 75.4% |
| >0.5 ng/mL | 49.2% | 59.6% |
| >2 ng/mL | 27.7% | 41.2% |
| >10 ng/mL | 12.5% | 21.0% |
Figure 1Receiver operating characteristic (ROC) curve analyses of the PGN, LPS, BDG, CRP, and PCT assays for the diagnosis of BSI (the diagnostic standard: blood culture combined with clinical diagnosis).
Efficacy evaluation of GN, LPS, BDG, CRP, and PCT in the diagnosis of BSI.
| PGN | LPS | BDG | CRP | PCT | |
|---|---|---|---|---|---|
| Cut-off Value | >163 pg/mL | >0.115 EU/mL | >66.87 pg/mL | >103.9 ng/mL | >0.295 ng/mL |
| Sensitivity | 83.33 | 77.91 | 83.78 | 74.14 | 45.45 |
| Specificity | 95.79 | 97.05 | 96.93 | 46.54 | 72.54 |
| AUC | 0.881 | 0.871 | 0.897 | 0.594 | 0.648 |
| 95%CI | (0.814–0.948) | (0.816–0.925) | (0.825–0.969) | (0.530–0.659) | (0.587–0.708) |
| <0.01 | <0.01 | <0.01 | <0.01 | <0.01 |